Hep C drug raises patient-choice concerns

January 12, 2015 12:52 PM

5 0

Hep C drug raises patient-choice concerns

At a time when the rising cost of medicines is causing consternation, an exclusive deal between Express Scripts Holding Co. , the nation’s largest pharmacy-benefits manager, and AbbVie Inc., a big drug maker, over a new hepatitis C treatment is generating concern about the implications for patient choice.

The deal came after the benefits manager spent a year railing about the prices charged by Gilead Sciences Inc., which until now has had a lock on the market. Fresh off FDA approval for its drug, AbbVie last month offered Express Scripts an undisclosed discount off its $84,000 list price. The newest ...

Also read: Pro-Western party in the lead in Montenegro vote: pollster

Read more

To category page